Clopidogrel Tablet, Film Coated
Product Images NDC 72789-469

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 72789-469). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72789469 Label (72789469)

Label for Clopidogrel USP 75 mg film-coated tablets from PD-Rx Pharmaceuticals, Inc. The label shows the product contains 90 tablets, includes warnings to keep out of reach of children and dosage instructions, and displays the NDC 72789-469-90. Additional details include lot number L24F58 and expiration date 07/2026.*

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal forest plot showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel 75 mg. The chart compares the change relative to Clopidogrel given alone with 90% confidence intervals for four PPIs: Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line chart showing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares patients receiving placebo plus aspirin versus clopidogrel plus aspirin, with clopidogrel showing lower cumulative event rates throughout the period. The chart includes a statistically significant P-value of 0.00009.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A forest plot comparing hazard ratios with 95% confidence intervals across various subgroups for Clopidogrel versus placebo. The subgroups include age, gender, race, elevated cardiac enzymes, diabetes, history of myocardial infarction or stroke, and concomitant medications such as heparin/LMWH, aspirin, GP IIb/IIIa antagonists, beta-blockers, and ACE inhibitors. The plot shows the relative favorability of Clopidogrel or placebo within each subgroup.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

A survival curve chart showing percentage dead before first discharge over days since randomization up to 28 days. It compares placebo with 1845 deaths (8.1%) and Clopidogrel with 1726 deaths (7.5%), indicating a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A line graph comparing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days between placebo and Clopidogrel groups. The graph shows a slightly lower event rate in the Clopidogrel group (9.2%) compared to placebo (10.1%), indicating a 9% proportional risk reduction.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart comparing outcomes in subgroups of patients treated with Clopidogrel versus placebo. The chart lists subgroups by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use, showing odds ratios with 99% confidence intervals for each subgroup and overall, indicating relative favoring of Clopidogrel or placebo.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line graph showing the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two lines compare aspirin and clopidogrel, with clopidogrel showing a slightly lower event rate over time. The graph includes a reported p-value of 0.045 indicating statistical comparison between treatments.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A data table presenting a comparison of outcomes for Stroke, MI, and PAD qualifying conditions between Clopidogrel and Aspirin groups, showing sample sizes, event counts and percentages, with a hazard ratio forest plot visually indicating which treatment is favored for each condition and overall outcomes.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel Bisulfate, showing the molecular arrangement of atoms and bonds characteristic of the active ingredient in this pharmaceutical product.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.